Shattuck Labs Inc (NASDAQ: STTK) — Perfil da empresa, notícias e dados financeiros
Shattuck Labs advances immunotherapy with a platform designed to stimulate the immune system against cancers and other diseases.
Shattuck Labs Inc
Shattuck Labs (NASDAQ:STTK) is dedicated to advancing the field of immunotherapy by developing a unique platform that harnesses the power of the immune system to fight disease. The company's innovative approach combines two potent mechanisms to stimulate an immune response against cancers and other diseases, aiming to provide new treatment options for patients. With a focus on transformative projects, Shattuck Labs is actively working on a pipeline of novel agents designed to engage and activate the immune system in a precise, controlled manner. Their objective is to bring groundbreaking therapies to the market, improving outcomes and quality of life for patients enduring various diseases. Shattuck Labs is committed to pushing the boundaries of scientific research to create a future where more diseases are not just treatable, but curable.
Resumo
Operações
Produtos e/ou serviços de Shattuck Labs Inc
- Development of SL-172154 (SIRPa-Fc-CD40L) aimed at oncology indications, addressing the dual mechanisms of CD47 immune checkpoint blockade and CD40 co-stimulation for enhanced antitumor activity.
- SL-279252 (PD1-Fc-OX40L) designed for immunotherapy in cancer, leveraging the PD-1 pathway blockade and OX40 agonism to potentially revive and stimulate the immune system against cancer cells.
- Research into novel Agonist Redirected Checkpoint (ARC) platform technology, creating fusion proteins that combine immune checkpoint blockade with costimulatory activation for potential cancer immunotherapy solutions.
- Collaborations with leading pharmaceutical companies to expand the application and leverage of ARC platform in various therapeutic areas, enhancing drug discovery and development processes.
- Commitment to pipeline expansion through strategic partnerships and acquisitions, focusing on innovative therapies that address unmet medical needs in oncology and other diseases.
- Investment in advanced manufacturing processes and facilities to ensure the high-quality production of its biologics, supporting rapid development and large-scale manufacturing capabilities for future products.
equipe executiva do Shattuck Labs Inc
- Taylor H. SchreiberCo-Founder, CEO & Director
- Andrew R. NeillChief Financial Officer
- Arunthathy Nirmalini PanditeChief Medical Officer
- Brad HuckabeeVice President of Accounting & SEC reporting
- Abhinav A. ShuklaChief Technical Officer
- Suresh de SilvaChief Scientific Officer
- Stephen StoutGeneral Counsel, Corporate Secretary and Chief Ethics & Compliance Officer
- Casi DeYoungChief Business Officer
- Thomas LampkinSenior Vice President of Regulatory Affairs
- Kelli CollinSenior Vice President of Quality
Últimas notícias sobre a Shattuck Labs Inc
Shattuck expands SL-325 development into hidradenitis suppurativa
United StatesShattuck Labs Q2 loss reaches $15.2 million
United StatesShattuck Labs reports positive Phase 1 data for Crohn’s disease candidate SL-325
United StatesShattuck Labs narrows annual loss to $48.8M, gears up for Phase 2 Crohn’s trial
United States
Principais indicadores financeiros
Resultados divulgados pela Shattuck Labs Inc, em USD.
- Cap. de mercado
- 596,2 mi
- Receita (TTM)
- 1 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.5
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 1 mi | -51,5 mi | -48,8 mi | |
| 5,7 mi | -80,6 mi | -75,4 mi | |
| 1,7 mi | -92 mi | -87,3 mi | |
| 652 mil | -103,3 mi | -100,6 mi |